Status:
Negotiations were not pursued
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Basal Cell Carcinoma (BCC), locally advanced in adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery
Last updated June 4, 2021
Status:
Negotiations were not pursued
Manufacturer:
Celgene Inc.
Indication:
Multiple Myeloma (Relapsed)
Last updated June 4, 2021
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation
Last updated June 3, 2021
Orkambi (lumacaftor/ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation
Last updated June 3, 2021
Status:
Concluded with an LOI
Manufacturer:
Juno Pharmaceuticals Corp.
Indication:
Deep vein thrombosis (treatment and prevention)
Last updated May 27, 2021
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Last updated May 21, 2021
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Rheumatoid Arthritis
Last updated May 10, 2021
Status:
Concluded without agreement
Manufacturer:
UCB Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated May 7, 2021
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Hodgkin's Lymphoma
Last updated April 28, 2021
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)
Last updated April 28, 2021